Holy Stone Healthcare Co., Ltd. (TPEX: 4194)
Health Care · Biotechnology · TW
NT$7.75
-4.32% today · -20.2% 1Y
Holy Stone Healthcare Co., Ltd. (TPEX: 4194) operates in the Biotechnology industry within the Health Care sector. The company is valued at $34.87M and employs 309 people.
Over the last twelve months the share price has lost 20.2%, trading between 5.80 and 10.05.
Tweenvest scores Holy Stone Healthcare Co., Ltd. across four factors: quality 45/100, value 62/100. Its strongest factor is value.
4194 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $34.87M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.86
- Dividend yield
- —
- Beta (5Y)
- 0.72
- 52-week high
- NT$10.05
- 52-week low
- NT$5.80
- Avg volume (3M)
- —
- Shares outstanding
- 145.97M
- Employees
- 309
- Next earnings
- —
About Holy Stone Healthcare Co., Ltd.
Holy Stone Healthcare Co., Ltd., together with its subsidiaries, develops and sells hyaluronic acid-related therapeutic products in Taiwan. The company offers RenehaVis and SportVis, which are injectable medical devices for osteoarthritis and soft tissue injuries; TRUD, a medical device that contains a mixture of hyaluronic acid used for the treatment and prevention of ulcerative colitis in inflammatory bowel disease (IBD); and GAF, a gel for anal fissure healing. It also develops IBD98-M, an oral capsule that is in a Phase IIa trial for ulcerative colitis; CA102N, a receptor-targeted chemotherapy that is in a Phase II trial for metastatic colorectal cancer, as well as in a pre-clinical stage for pancreatic ductal adenocarcinoma and a discovery stage for triple-negative breast cancer; ND108E, a CNS-targeted HA conjugate that is in a pre-clinical trial for Alzheimer’s disease; AMD112, a non-invasive HA-conjugated small molecule therapy that is in a pre-clinical trial for wet age-related macular degeneration and other neovascular retinal diseases; and HylCaryo, a hyaluronic acid (HA)-derived nanoparticle platform in a discovery stage. In addition, the company engages in general investment; development and sale of medical devices; biotechnology services; and patent application for pharmaceutical products. Holy Stone Healthcare Co., Ltd. was founded in 2001 and is headquartered in Taipei, Taiwan.
- ISIN
- TW0004194006
- Founded
- 2001
- Listed since
- Dec 13, 2013
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Transcenta Holding LimitedSEHK: 6628 | $35.36M | HK$0.65 | -19.75% |
| NanoViricides, Inc.NYSEAM: NNVC | $35.22M | $1.38 | +6.15% |
| Elutia Inc.NasdaqCM: ELUT | $35.17M | $0.79 | -3.54% |
| Lite Strategy, Inc.NasdaqCM: LITS | $34.97M | $1.15 | -9.45% |
| Edesa Biotech, Inc.NasdaqCM: EDSA | $34.72M | $2.57 | -26.78% |
| Biomark Diagnostics Inc.DB: 20B | $34.02M | €0.28 | -4.70% |
| CervoMed Inc.NasdaqCM: CRVO | $33.87M | $2.24 | -30.43% |
| Cell Source, Inc.OTCPK: CLCS | $33.63M | $0.49 | -10.45% |
Figures last refreshed Oct 18, 2026.